MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

glimepiride

Search medical newsFind research, conditions and clinical updates
  • Home
  • glimepiride
SLC2A2遗传变异如何影响格列美脲疗效:来自 GRADE 试验的血糖反应新发现
Posted inClinical Updates Diabetes & Endocrinology

Genetic Insights into Glycemic Response: Role of SLC2A2 Variants in Sulfonylurea Efficacy from the GRADE Trial

Posted by By MedXY 11/12/2026
This article explores how common genetic variants near SLC2A2 affect glycemic response to glimepiride in type 2 diabetes, highlighting potential for precision medicine in second-line diabetes therapy.
Read More
Empagliflozin, Pioglitazone or Glimepiride as Third Agents with Metformin + DPP‑4 Inhibitor: Similar HbA1c Drops but Different Trade‑offs
Posted inDiabetes & Endocrinology news

Empagliflozin, Pioglitazone or Glimepiride as Third Agents with Metformin + DPP‑4 Inhibitor: Similar HbA1c Drops but Different Trade‑offs

Posted by By MedXY 11/17/2025
A 24‑week randomized phase 4 trial found comparable HbA1c reductions when adding empagliflozin, pioglitazone or glimepiride to metformin plus a DPP‑4 inhibitor; metabolic and safety profiles differed, arguing for individualized third‑line selection.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Beyond Abstinence: Multidisciplinary Approaches Enhance Long-Term Outcomes After Liver Transplantation for Alcohol-Associated Liver Disease
  • Assessing Accuracy and Utility of Melanoma Risk Prediction Models in an Australian Cohort
  • A Minimum Standard Set for Reporting Lymphatic Surgery Outcomes: What the Society of Lymphatic Surgery Consensus Means for Practice
  • Putting People First in ICU Care: ESICM’s 2026 Consensus on Human-Centred Partnership
  • Force Multiplication in Body Contouring: Enhancing Access and Conversion through Advanced Practice Provider Clinics
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top